|
Status |
Public on Feb 07, 2013 |
Title |
Control M1 [miRNA] |
Sample type |
RNA |
|
|
Source name |
Primary human Neurons
|
Organism |
Homo sapiens |
Characteristics |
cell type: Primary human Neurons agent: untreated
|
Treatment protocol |
Cells were treated with 10 pg/ml of Vpr protein kindly received from Dr Eric Cohen, University of Montreal-Canada for 24 hours.
|
Growth protocol |
Primary human neurons (HN) (5 x 105) purchased from ScienCell Research Laboratories (Carlsbad, CA) were grown in DMEM + 10% FBS on MatTek glass bottom plates treated with collagen (MatTek, Ashland, MA).
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA). 750 ng of total RNA was used for miRNA array analysis using Agilent-019118 Human miRNA Microarray 2.0 G4470B (miRNA ID version)
|
Label |
Hy5
|
Label protocol |
RNA was labeled using the miRCURY LNATM miRNA, Hy5 Power Labeling Kit (Exiqon) as per manufacturer’s recommendations using Maui SC Hybridization Chambers (BioMicro Systems, Salt Lake City, UT).
|
|
|
Hybridization protocol |
Standard Agilent protocol.
|
Scan protocol |
Array chips were scanned using Axon GenePix Scanner (Molecular Devices, Downingtown, PA) and Genepix 4000 image capture software (Molecular Devices, Downingtown, PA).
|
Data processing |
Quantile normalization was used using JMP Genomics (JMP, Cary, NC) at Harvard Catalyst - Laboratory for Innovative Translational Technology (HC-LITT) and differentially regulated miRNAs were determined. Untreated cells were used as control.
|
|
|
Submission date |
Feb 07, 2013 |
Last update date |
Feb 12, 2013 |
Contact name |
Bassel E Sawaya |
E-mail(s) |
sawaya@temple.edu
|
Phone |
2157075446
|
Organization name |
Temple University
|
Department |
Neurology
|
Street address |
3307 N. Broad Street
|
City |
Philadelphia |
State/province |
PA |
ZIP/Postal code |
19140 |
Country |
USA |
|
|
Platform ID |
GPL8227 |
Series (1) |
GSE44266 |
Deregulation of microRNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders. |
|